Effects of chronic wound fluid on the structure and biological activity of becaplermin (rhPDGF-BB) and becaplermin gel.
In this study, the effects of chronic wound fluid on the structure and biological activity of becaplermin (recombinant human platelet-derived growth factor-BB [rhPDGF-BB]) were evaluated. Wound fluid was collected from 12 subjects with diabetic ulcers or pressure ulcers. Wound fluid +/- becaplermin was added to cell cultures before- and after incubation for 12 hours at 37 degrees C or after 12 hours' topical treatment. Biological activity, concentration, and immunogenicity were determined by [3H]thymidine incorporation into quiescent human foreskin fibroblasts, enzyme-linked immunosorbent assay (ELISA), and Western blot analysis, respectively. No PDGF-BB or mitogenic activity was detected in chronic wound fluid alone. Mitogenic activity was present in post-treatment samples from becaplermin-treated subjects but not placebo-treated subjects. Exposure to chronic wound fluid for 12 hours did not alter the amount, banding pattern, or mitogenic activity of becaplermin. Biologically active becaplermin remains in wound fluid 12 hours after topical application of becaplermin gel.
Department of Surgery, Morristown Memorial Hospital, New Jersey 07962-1956, USA.
J J
JJ
Castronuovo
I
I
Ghobrial
A M
AM
Giusti
S
S
Rudolph
J M
JM
Smiell
D000328:Adult; D000925:Anticoagulants / Q000494:pharmacology*; D000077214:Becaplermin; D002908:Chronic Disease; D017719:Diabetic Foot; D006801:Humans; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology*; D003668:Pressure Ulcer; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins / Q000494:pharmacology; D013329:Structure-Activity Relationship; D014945:Wound Healing / Q000502:physiology*
D000925:Anticoagulants; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; D000077214:Becaplermin